Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 30Capecitabine 26Fluorouracil 20Irinotecan 19tislelizumab 18apatinib 16Paclitaxel 13Cisplatin 13S 1 (combination) 12Radiotherapy 12Leucovorin 11Bevacizumab 11Laparoscopy 9Drug Therapy 9Cetuximab 9sintilimab 8Endoscopic Mucosal Resection 8Radiation 7Gemcitabine 7Docetaxel 7camrelizumab 6XELOX 6Surgical Procedures, Operative 6Propranolol 6Nivolumab 6Neoadjuvant Therapy 6Immune Checkpoint Inhibitors 6Folfox protocol 6Levoleucovorin 5HMPL-013 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Blood Cell Count × Gastrointestinal × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡